Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 1
1976 2
1977 1
1978 2
1979 2
1980 1
1983 1
1984 2
1986 1
1988 1
1989 1
1990 1
1991 1
1993 5
1994 2
1995 8
1996 1
1997 2
1998 3
1999 2
2000 5
2001 5
2002 4
2003 5
2004 7
2005 3
2006 2
2007 7
2008 6
2009 4
2010 3
2011 1
2013 5
2014 2
2015 1
2017 2
2018 4
2019 2
2020 3
2021 2
2022 7
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A. Katzenschlager R, et al. Lancet Neurol. 2018 Sep;17(9):749-759. doi: 10.1016/S1474-4422(18)30239-4. Epub 2018 Jul 25. Lancet Neurol. 2018. PMID: 30055903 Clinical Trial.
Apomorphine was well tolerated without any unexpected safety signals. Six patients in the apomorphine group withdrew from the study because of treatment-related adverse events. ...
Apomorphine was well tolerated without any unexpected safety signals. Six patients in the apomorphine group withdrew from the
Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience.
Henriksen T, Katzenschlager R, Bhidayasiri R, Staines H, Lockhart D, Lees A. Henriksen T, et al. J Neural Transm (Vienna). 2023 Nov;130(11):1475-1484. doi: 10.1007/s00702-023-02686-7. Epub 2023 Sep 1. J Neural Transm (Vienna). 2023. PMID: 37658155 Free PMC article. Clinical Trial.
A post hoc analysis of data from the TOLEDO randomized clinical trial of apomorphine infusion was conducted along with an analysis of 'real world' experience from 13 movement disorders specialists using a questionnaire that focused on starting patients on apomorphine
A post hoc analysis of data from the TOLEDO randomized clinical trial of apomorphine infusion was conducted along with an analysis of …
Apomorphine for the Treatment of Erectile Dysfunction: Systematic Review and Meta-Analysis.
Guillén V, Rueda JR, Lopez-Argumedo M, Solà I, Ballesteros J. Guillén V, et al. Arch Sex Behav. 2020 Nov;49(8):2963-2979. doi: 10.1007/s10508-020-01817-5. Epub 2020 Sep 22. Arch Sex Behav. 2020. PMID: 32964351
Sublingual apomorphine could be an option in patients with erectile dysfunction who cannot take phosphodiesterase type 5 inhibitors (e.g., using nitrates). We have completed a systematic review to evaluate the effects of sublingual apomorphine comparing with placebo …
Sublingual apomorphine could be an option in patients with erectile dysfunction who cannot take phosphodiesterase type 5 inhibitors ( …
Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
Stocchi F, Rascol O, Poewe W, Chaudhuri KR, Kassubek J, Lopez Manzanares L, Zhang Y, Bowling A, Pappert E, Wu S; CTH-302 Study Investigators. Stocchi F, et al. J Parkinsons Dis. 2023;13(8):1329-1342. doi: 10.3233/JPD-230072. J Parkinsons Dis. 2023. PMID: 37980683 Free PMC article. Clinical Trial.
BACKGROUND: Apomorphine sublingual film (SL-APO) and subcutaneous apomorphine (SC-APO) have been used for the treatment of OFF episodes in Parkinson's disease (PD). ...
BACKGROUND: Apomorphine sublingual film (SL-APO) and subcutaneous apomorphine (SC-APO) have been used for the treatment of OFF …
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, Pahwa R, Leinonen M, Bhargava P, Sciarappa K, Navia B, Blum D; CTH-300 Study investigators. Olanow CW, et al. Lancet Neurol. 2020 Feb;19(2):135-144. doi: 10.1016/S1474-4422(19)30396-5. Epub 2019 Dec 7. Lancet Neurol. 2020. PMID: 31818699 Clinical Trial.
Mild-to-moderate oropharyngeal events were the most common side-effect, reported in 17 (31%) of 54 patients receiving apomorphine sublingual film and in four (7%) of 55 patients receiving placebo, leading to treatment discontinuation in nine (17%) patients treated with …
Mild-to-moderate oropharyngeal events were the most common side-effect, reported in 17 (31%) of 54 patients receiving apomorphine sub …
Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study.
De Cock VC, Dodet P, Leu-Semenescu S, Aerts C, Castelnovo G, Abril B, Drapier S, Olivet H, Corbillé AG, Leclair-Visonneau L, Sallansonnet-Froment M, Lebouteux M, Anheim M, Ruppert E, Vitello N, Eusebio A, Lambert I, Marques A, Fantini ML, Devos D, Monaca C, Benard-Serre N, Lacombe S, Vidailhet M, Arnulf I, Doulazmi M, Roze E. De Cock VC, et al. Lancet Neurol. 2022 May;21(5):428-437. doi: 10.1016/S1474-4422(22)00085-0. Lancet Neurol. 2022. PMID: 35429481 Clinical Trial.
We aimed to test the safety and efficacy of subcutaneous night-time only apomorphine infusion in patients with Parkinson's disease and insomnia. ...Apomorphine was associated with more frequent dizziness than was placebo (seven [15%] vs 0; p=0.041). ...
We aimed to test the safety and efficacy of subcutaneous night-time only apomorphine infusion in patients with Parkinson's disease an …
Apomorphine and schizophrenia.
Johns CA, Levy MI, Davis BM, Mohs RC, Kendler KS, Mathe AA, Trigos G, Horvath TB, Davis KL. Johns CA, et al. Psychopharmacol Bull. 1984 Winter;20(1):103-7. Psychopharmacol Bull. 1984. PMID: 6718635 Clinical Trial. No abstract available.
Apomorphine: an update of clinical trial results.
Heaton JP. Heaton JP. Int J Impot Res. 2000 Oct;12 Suppl 4:S67-73. doi: 10.1038/sj.ijir.3900581. Int J Impot Res. 2000. PMID: 11035390
Over 3000 men have received apomorphine SL and over 75,000 doses have been taken. In the first three phase III parallel arm cross-over double-blind studies 854 patients were given a total of 8263 tablets of apomorphine SL in 2 and 4 mg doses. ...The most common but …
Over 3000 men have received apomorphine SL and over 75,000 doses have been taken. In the first three phase III parallel arm cross-ove …
Apomorphine test for dopaminergic responsiveness: a dose assessment study.
Bonuccelli U, Piccini P, Del Dotto P, Rossi G, Corsini GU, Muratorio A. Bonuccelli U, et al. Mov Disord. 1993 Apr;8(2):158-64. doi: 10.1002/mds.870080207. Mov Disord. 1993. PMID: 8474482 Clinical Trial.
Twenty-seven patients of 37 showed a positive response to apomorphine, and 10 had a negative response. All positive responses to the apomorphine test were obtained with 50 or 100 micrograms/kg doses. ...Our data indicate that subcutaneous apomorphine at the d …
Twenty-seven patients of 37 showed a positive response to apomorphine, and 10 had a negative response. All positive responses to the …
The apomorphine test in heroin addicts.
Casas M, Guardia J, Prat G, Trujols J. Casas M, et al. Addiction. 1995 Jun;90(6):831-5. doi: 10.1046/j.1360-0443.1995.90683111.x. Addiction. 1995. PMID: 7633301 Clinical Trial.
In humans, the in vivo study of the sensitivity of the dopamine neurotransmitter system in Parkinson's patients can be done by means of the apomorphine test, which consists of measuring the number of yawns induced by the subcutaneous administration of low doses of apomo
In humans, the in vivo study of the sensitivity of the dopamine neurotransmitter system in Parkinson's patients can be done by means of the …
117 results